[Drug-induced parkinsonism].
Shiio
Yasushi
Y
Department of Neurology, Toranomon Hospital.
D000547:Amantadine / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001549:Benzamides / Q000009:adverse effects; D002090:Butyrophenones / Q000009:adverse effects; D002121:Calcium Channel Blockers / Q000009:adverse effects; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000009:adverse effects; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D020734:Parkinsonian Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D010640:Phenothiazines / Q000009:adverse effects; D013997:Time Factors
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D001549:Benzamides; D002090:Butyrophenones; D002121:Calcium Channel Blockers; D018680:Cholinergic Antagonists; D005765:Gastrointestinal Agents; D006634:Histamine H1 Antagonists; D010640:Phenothiazines; D000547:Amantadine